Imugene adds to scientific board

Imugene (ASX:IMU) has appointed Dr Christoph Zielinski and Dr Ursula Wiedermann to its scientific advisory board.

Dr Zielinski is director of the Clinical Division of Oncology and chairman of the Department of Medicine at the Medical University of Vienna, Austria. He is also coordinator of the university’s Comprehensive Cancer Center and president of the Central European Cooperative Oncology Group.

Dr Wiedermann is professor of vaccinology and head of the Institute of Specific Prophylaxis and Tropical Medicine of the Medical University of Vienna, as well as a visiting professor at Sweden’s University of Goteborg.

“We are extremely pleased that two scientists of such substantial international calibre ... have joined the Imugene Scientific Advisory Board,” Imugene executive director Dr Nick Ede said. “They are both internationally recognised as leaders in oncology, vaccinology and immunology.”

Both scientists have played important roles in the development of HER-Vaxx, a vaccine which has shown signs of triggering an immune response in certain types of breast, gastric, pancreatic and ovarian cancers.

Dr Wiederman was principal investigator during the preclinical development period and, together with Dr Zelinski’s team, also conducted the phase I trial in metastatic breast cancer.

Imugene acquired the rights to HER-Vaxx last year, with the all-stock acquisition of Biolife Science.

Imugene (ASX:IMU) shares were trading unchanged at $0.019 as of around 1.30 pm on Tuesday.